The FDA has instituted a clinical hold on Magenta Therapeutics Inc's
MGTA Investigational New Drug Application (IND) of MGTA-117.
- In June, the IND was filed to initiate a Phase 1/2 trial of MGTA-117 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- The FDA has asked Magenta to develop an additional bioassay to be used in conjunction with the PK/PD model to inform dose escalation decisions in addition to safety monitoring.
- The clinical hold does not relate to the toxicology or manufacturing of MGTA-117.
- Magenta has initiated bioassay development.
- The Phase 1/2 clinical trial of MGTA-117 is intended to evaluate its safety, pharmacokinetics (PK), and pharmacodynamics (PD) as a single agent in the relapsed/refractory AML and MDS patient population.
- Magenta ended Q2 2021 with more than $200 million in cash sufficient to execute its existing plans.
- Magenta's MGTA-117 program is the Company's lead targeted conditioning product candidate, an antibody-drug conjugate (ADC) designed to deplete hematopoietic stem cells (HSCs) selectively.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.